Listed by the USPTO as KAUFMAN, CLAIRE M
Tech Center 1600 • Art Units: 1646 1653 1654 1674
This examiner grants 63% of resolved cases
Claire M. Kaufman works in tech center 1600 and art unit 1646, with 577 resolved cases. The allowance rate is 63.3%, and the median time to allowance is 1093 days. Interview lift is 51.0%, indicating a strong favorable association between interviews and allowance outcomes in the available record.
The leading companies are Novartis AG, Amgen Inc., and Janssen Pharmaceuticals Inc. The leading firms are Clark+Elbing LLP, BakerHostetler, and Bayramoglu Law Offices LLC. Practitioners may give interviews a prominent role in prosecution planning, particularly when the discussion can lead to focused amendments or clearer distinctions over the cited art.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18019467 | TREATMENT OF CLL | Final Rejection | NOVARTIS AG |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | Non-Final OA | NOVARTIS AG |
| 17921793 | PHARMACEUTICAL FORMULATION | Final Rejection | AMGEN INC. |
| 17774232 | MULTITARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES | Non-Final OA | AMGEN INC. |
| 18392954 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18567967 | POLYPEPTIDES TARGETING CD70-POSITIVE CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18175225 | METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | Non-Final OA | Pfizer Inc. |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | Non-Final OA | Genmab A/S |
| 17924540 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Adagene AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.3% of resolved applications examined by Claire M Kaufman were allowed (577 resolved cases), compared with 40.9% across Art Unit 1646 over the last five years.
This examiner's interview lift is +51.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Claire M Kaufman took 1,093 days on average from filing to allowance.
Claire M Kaufman examines applications in Art Unit 1646 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
